A signature of platelet reactivity in CBC scattergrams reveals genetic predictors of thrombotic disease risk

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research has been conducted using the UK Biobank Resource under Application Number 13745. We are grateful to the Lowy Foundation USA for supporting this work. We are grateful to Mr Stephen Garner for generating part of the Cambridge PFC FC dataset and for his invaluable advice on the operation of Sysmex haematology analysers. We thank Drs. Jarob Saker and Joachim Linssen of Sysmex Europe and Rob Gillions of UK Biobank for invaluable technical assistance and advice. We gratefully acknowledge the participation of all UK Biobank, NIHR Cambridge BioResource, and INTERVAL volunteers. We thank members of the Cambridge BioResource Scientific Advisory Board and Management Committee for their support of our study and the NIHR Cambridge Biomedical Research Centre for funding (RG64219). Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England, which has supported field work and other elements of the trial. DNA extraction and genotyping were co-funded by the National Institute for Health and Care Research (NIHR), the NIHR BioResource and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The academic coordinating centre for INTERVAL was supported by core funding from the: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), NIHR Blood and Transplant Research Unit in Donor Health and Behaviour (NIHR203337), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014; NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR, NHSBT or the Department of Health and Social Care. A complete list of the investigators and contributors to the INTERVAL trial is provided in Di Angelantonio et al. (Lancet 2017)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Studies involving participants in the Cambridge Platelet Function Cohort received approval from the National Research Ethics Service Committee for East of England - Cambridge East, with the following Research Ethics Committee (REC) reference numbers: REC 05/Q0104/27; REC 05/Q0104/27; BluePrint REC 12/EE/0040; HIPSCI - REC 09/H0304/77, V2 04/01/2013 and V3 15/03/2013; and Genes and Platelets, REC 10/H0304/65. The INTERVAL study received approval from the National Research Ethics Service Committee for East of England - Cambridge East, with reference number 11/EE/0538. The UK Biobank study received approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB). As such, researchers do not require separate ethical clearance and can operate under the RTB approval.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes